help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bernardi, R. J.
Right arrow Articles by Trump, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernardi, R. J.
Right arrow Articles by Trump, D. L.
Endocrinology Vol. 143, No. 7 2508-2514
Copyright © 2002 by The Endocrine Society

CANCER

Antiproliferative Effects of 1{alpha},25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells

Ronald J. Bernardi, Candace S. Johnson, Ruth A. Modzelewski and Donald L. Trump

Departments of Pharmacology (R.J.B., C.S.J., R.A.M.), Medicine (C.S.J., D.L.T.), and Urology (D.L.T.), University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213

Address all correspondence and requests for reprints to: Dr. Donald L. Trump, Department of Medicine, University of Pittsburgh, UPMC Montefiore, N723, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213. E-mail: . trumpdl{at}msx.upmc.edu

Although there is abundant evidence that 1{alpha},25-dihydroxyvitamin D3 [1,25-(OH)2D3] inhibits the growth of several cancer cell types, inhibition of angiogenesis may also play a role in mediating the antitumor effects of 1,25-(OH)2D3. We examined the ability of 1,25-(OH)2D3 to inhibit the growth of tumor-derived endothelial cells (TDECs) and normal endothelial cells and to modulate angiogenic signaling. 1,25-(OH)2D3 inhibited the growth of TDECs from two tumor models at nanomolar concentrations, but was less potent against normal aortic or yolk sac endothelial cells. The vitamin D analogs Ro-25-6760, EB1089, and ILX23-7553 were also potent inhibitors of TDEC proliferation. Furthermore, the combination of 1,25-(OH)2D3 and dexamethasone had greater activity than either agent alone. 1,25-(OH)2D3 increased vitamin D receptor and p27Kip1 protein levels in TDECs, whereas phospho-ERK1/2 and phospho-Akt levels were reduced. These changes were not observed in normal aortic endothelial cells. In squamous cell carcinoma and radiation-induced fibrosarcoma-1 cells, 1,25-(OH)2D3 treatment caused a reduction in the angiogenic signaling molecule, angiopoietin-2. In conclusion, 1,25-(OH)2D3 and its analogs directly inhibit TDEC proliferation at concentrations comparable to those required to inhibit tumor cells. Further, 1,25-(OH)2D3 modulates cell cycle and survival signaling in TDECs and affects angiogenic signaling in cancer cells. Thus, our work supports the hypothesis that angiogenesis inhibition plays a role in the antitumor effects of 1,25-(OH)2D3.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Myrthue, B. L.S. Rademacher, J. Pittsenbarger, B. Kutyba-Brooks, M. Gantner, D. Z. Qian, and T. M. Beer
The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells
Clin. Cancer Res., June 1, 2008; 14(11): 3562 - 3570.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. E. Valrance, A. H. Brunet, and J. Welsh
Vitamin D Receptor-Dependent Inhibition of Mammary Tumor Growth by EB1089 and Ultraviolet Radiation in Vivo
Endocrinology, October 1, 2007; 148(10): 4887 - 4894.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. M. Albert, E. A. Scheef, S. Wang, F. Mehraein, S. R. Darjatmoko, C. M. Sorenson, and N. Sheibani
Calcitriol Is a Potent Inhibitor of Retinal Neovascularization
Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2327 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
N. Parekh, R. J. Chappell, A. E. Millen, D. M. Albert, and J. A. Mares
Association Between Vitamin D and Age-Related Macular Degeneration in the Third National Health and Nutrition Examination Survey, 1988 Through 1994
Arch Ophthalmol, May 1, 2007; 125(5): 661 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Ben-Shoshan, S. Amir, D. T. Dang, L. H. Dang, Y. Weisman, and N. J. Mabjeesh
1{alpha},25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells
Mol. Cancer Ther., April 1, 2007; 6(4): 1433 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Chung, A. R. Karpf, J. R. Muindi, J. M. Conroy, N. J. Nowak, C. S. Johnson, and D. L. Trump
Epigenetic Silencing of CYP24 in Tumor-derived Endothelial Cells Contributes to Selective Growth Inhibition by Calcitriol
J. Biol. Chem., March 23, 2007; 282(12): 8704 - 8714.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy.
Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
I. Chung, M. K. Wong, G. Flynn, W.-d. Yu, C. S. Johnson, and D. L. Trump
Differential Antiproliferative Effects of Calcitriol on Tumor-Derived and Matrigel-Derived Endothelial Cells.
Cancer Res., September 1, 2006; 66(17): 8565 - 8573.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Masuda and G. Jones
Promise of vitamin D analogues in the treatment of hyperproliferative conditions.
Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Berwick, B. K. Armstrong, L. Ben-Porat, J. Fine, A. Kricker, C. Eberle, and R. Barnhill
Sun Exposure and Mortality From Melanoma
J Natl Cancer Inst, February 2, 2005; 97(3): 195 - 199.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. C. Fleet
Rapid, Membrane-Initiated Actions of 1,25 Dihydroxyvitamin D: What Are They and What Do They Mean?
J. Nutr., December 1, 2004; 134(12): 3215 - 3218.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. V. Stewart and N. L. Weigel
Vitamin D and Prostate Cancer
Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. M. Beer and A. Myrthue
Calcitriol in cancer treatment: From the lab to the clinic
Mol. Cancer Ther., March 1, 2004; 3(3): 373 - 381.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
O. Morales, M. K. R. Samuelsson, U. Lindgren, and L.-A. Haldosen
Effects of 1{alpha},25-Dihydroxyvitamin D3 and Growth Hormone on Apoptosis and Proliferation in UMR 106 Osteoblast-Like Cells
Endocrinology, January 1, 2004; 145(1): 87 - 94.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Crescioli, P. Ferruzzi, A. Caporali, R. Mancina, A. Comerci, M. Muratori, M. Scaltriti, G. B. Vannelli, S. Smiroldo, R. Mariani, et al.
Inhibition of Spontaneous and Androgen-Induced Prostate Growth by a Nonhypercalcemic Calcitriol Analog
Endocrinology, July 1, 2003; 144(7): 3046 - 3057.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society